Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Akanksha S MahajanDepartment of Neurological Surgery, The Brain Tumor Center, Washington University School of Medicine, Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110.ORCID 0009-0000-0085-555X
Corey DussoldDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
Seunghyun KimDepartment of Neurological Surgery, The Brain Tumor Center, Washington University School of Medicine, Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110.
Rachel JarvisDepartment of Neurological Surgery, The Brain Tumor Center, Washington University School of Medicine, Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110.
Lisa A HurleyDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
Serena Tommasini-GhelfiKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
Connor M ForsythInterdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, IL 60208.ORCID 0000-0002-2576-861X
Bin ZhangDivision of Hematology and Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60208.
Jason MiskaDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.ORCID 0000-0001-9608-2810
Amy B HeimbergerDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.ORCID 0000-0002-9970-8695
Chad A MirkinInternational Institute for Nanotechnology, Northwestern University, Evanston, IL 60208.ORCID 0000-0002-6634-7627
Alexander H SteghDepartment of Neurological Surgery, The Brain Tumor Center, Washington University School of Medicine, Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110.ORCID 0000-0003-2395-7967
Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hui Zhang · 2018 to 2026
$21.4M
CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4M
Modulation of Microglia and T Cell Interactions in Malignant GliomaR01CA120813 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, RAO, GANESH · 2007 to 2025
$4.7M
A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and RadiationR01CA272639 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Amy Beth Heimberger, Priya U. Kumthekar · 2023 to 2026
$2.3M
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.R01CA275430 · NCI · WASHINGTON UNIVERSITY · PI MIRKIN, CHAD A., STEGH, ALEXANDER H. · 2022 to 2025
$2.3M
Stinging the Glioma Immune LandscapeR01NS120547 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, RAO, ARVIND · 2020 to 2023
$1.1M
IVIS Spectrum CT Preclinical In Vivo Imaging SystemS10OD027042 · OD · WASHINGTON UNIVERSITY · PI ACHILEFU, SAMUEL · 2019 to 2019
$599k
Multispectral Optoacoustic Tomography (MSOT) SystemS10OD025264 · OD · WASHINGTON UNIVERSITY · PI ACHILEFU, SAMUEL · 2018 to 2018
$544k
HHS | NIH | National Cancer Institute (NCI) P30CA060553HHS | NIH | National Cancer Institute (NCI) P30CA09184HHS | NIH | National Cancer Institute (NCI) P50CA221747HHS | NIH | National Cancer Institute (NCI) R01CA120813HHS | NIH | National Cancer Institute (NCI) R01CA27263HHS | NIH | National Cancer Institute (NCI) R01CA275430HHS | NIH | National Cancer Institute (NCI) S10OD02526HHS | NIH | National Cancer Institute (NCI) S10OD027042HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS12054NCI NIH HHS P30 CA060553NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA221747NCI NIH HHS R01 CA120813NCI NIH HHS R01 CA272639NCI NIH HHS R01 CA275430NCI NIH HHS T32 CA009560NIH HHS S10 OD025264NIH HHS S10 OD027042NINDS NIH HHS R01 NS120547
6 · The paper itself
Abstract
The cyclic GMP-AMP synthase-Stimulator of Interferon Genes (cGAS-STING) pathway is an important DNA-sensing mechanism that increases T cell trafficking and activation in tumors and reverses the immunosuppressive phenotype of myeloid cells. Therefore, direct STING targeting using synthetic cyclic dinucleotides (CDNs) is an attractive strategy for treating lymphocyte-depleted and myeloid cell-enriched tumors, such as glioblastoma (GBM). However, inadequate bioavailability and poor cellular accumulation limit the clinical development of CDNs, particularly for noninvasive administration strategies. Spherical nucleic acids (SNAs) have emerged as promising modular constructs for creating therapeutic lead compounds for many diseases, including different forms of cancer. Here, we report the development of cGAS-activating SNAs that consist of gold nanoparticle cores functionalized with a shell of densely packed interferon-stimulatory DNA oligonucleotides (ISD
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
cGAS-agonistic spherical nucleic acids reprogram the glioblastoma immune microenvironment and promote antitumor immunity. · full record | OpenQuestion